Rofecoxib, Merck, and the FDA

N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8.
No abstract available

Publication types

  • Comment
  • Historical Article
  • Letter

MeSH terms

  • Aspirin / therapeutic use
  • Cardiovascular Diseases / chemically induced*
  • Celecoxib
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / history
  • Drug Approval / history
  • Drug Interactions
  • Gastrointestinal Diseases / chemically induced
  • Gastrointestinal Diseases / history
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Lactones / adverse effects*
  • Lactones / history
  • Platelet Aggregation Inhibitors / therapeutic use
  • Pyrazoles / adverse effects
  • Pyrazoles / history
  • Sulfonamides / adverse effects
  • Sulfonamides / history
  • Sulfones / adverse effects*
  • Sulfones / history
  • United States
  • United States Food and Drug Administration

Substances

  • Cyclooxygenase Inhibitors
  • Lactones
  • Platelet Aggregation Inhibitors
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Celecoxib
  • Aspirin